Children’s Hospital at Columbia Medical University
From 2014-2018 tay-bandz has funded Precision Medicine at Columbia University Medical Center. The practice of Precision medicine involves genome sequencing of an individual child’s tumor to identify mutations in their DNA. Identification will enable more precise targeted treatment and prevention that will improve outcomes, decrease adverse events, as well as refine or revise diagnosis and achieve more accurate prognosis.
Customized treatments targeting the precise characteristics of a child’s tumor is a groundbreaking change from the one-size fits all approach used to date.
What distinguishes Columbia as a leader in the field of personalized medicine are the breadth and depth of clinical expertise across disciplines, the rich and diverse patient population they attract, and access to world-renowned research faculty. At Columbia success is measured one patient/one family at a time.
From 2009-2010 tay-bandz funded a pre-clinical testing program used to establish cell lines from patients who have rare tumors and to then use them to test novel therapeutics.
From 2005-2009 tay-bandz supported several faucets of solid tumor research including research to understand the biology of pediatric solid tumors. The goals were to understand the angiogenesis of pediatric solid tumors, evaluate agents in preclinical models and develop clinical trials with antiangiogenic agents. Additionally, tay-bandz supported the Development Therapeutics Program.
Memorial Sloan Kettering
The anti-body study initially funded by tay-bandz in 2014 has reached completion. The antibody was used for a specific cancer that typically hits 15-18 years old and has a very poor prognosis.
Overall, the results are very encouraging and enough to proceed to an expansion and incorporate it into the overall treatment plan for patients with this type of cancer.
In 2018, tay-bandz funded a second part of this trial which will measure, by sophisticated methods, if any cancer cells exist after the patient has received the anti-body,
The National Institute of Health
tay-bandz has funded the completion of a clinical grade master cell bank to support development of a new immunotherapy based vaccine for patients with pediatric sarcomas.
MD Anderson Cancer Center
MD Anderson Cancer Center: tay-bandz has funded research focused on pediatric osteosarcoma, a soft tissue sarcoma that can occur in adolescents and young adults.
One day in the life of a childhood cancer patient can be an eternity
Our goal has been and always will be to help children with cancer by funding cutting edge research that can impact their lives now, not years and miles of bureaucratic red tape from now.
We will never stop pushing the boundaries of conventional therapies, dated public policy, and the logjams that keep good drugs in the lab and out of the clinic. All our children deserve a bright and healthy future.